PSME2 Antibody

What is the primary function of PSME2 in cellular processes?

PSME2 forms a critical part of the PA28 activator complex that enhances the generation of class I binding peptides by modifying proteasome cleavage patterns. It's implicated in immunoproteasome assembly and required for efficient antigen processing . PSME2 plays a significant role in protein degradation mediated by the proteasome and is particularly important in immune-related protein processing mechanisms . In healthy individuals, PSME2 is reportedly inactive, but becomes activated in specific disease conditions, suggesting its contextual regulatory functions .

Which experimental applications are most suitable for PSME2 antibodies?

PSME2 antibodies have demonstrated effectiveness across multiple applications, including:

• Western Blot (WB): Validated for human, mouse, and rat samples

• Immunohistochemistry (IHC): Particularly effective for human kidney tissue and tumor samples

• Immunoprecipitation (IP): Successfully tested in MCF-7 cells

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Validated in cell lines like MCF-7 and HeLa

• Flow Cytometry: Effective for intracellular detection in multiple cell types

• ELISA: Validated with recombinant human PSME2 protein

What are the optimal tissue preparation methods for PSME2 immunohistochemistry?

For optimal IHC results with PSME2 antibodies, heat-mediated antigen retrieval is essential. Two validated approaches include:

• TE buffer pH 9.0 (preferred method): This alkaline buffer typically provides superior epitope retrieval for PSME2

• Citrate buffer pH 6.0 (alternative method): Can be used as a secondary option if TE buffer doesn't provide optimal results

For paraformaldehyde-fixed samples (4%), a 1:1000-1:4000 antibody dilution range is recommended for IHC applications, though optimal concentration should be determined experimentally for each tissue type .

How is PSME2 expression altered in cancer tissues compared to normal tissues?

PSME2 demonstrates significant differential expression across multiple cancer types:

• Breast cancer: PSME2 is upregulated in tumor tissues and correlated with immunologically "hot" tumor microenvironments

• Clear cell renal cell carcinoma (ccRCC): PSME2 shows higher expression in cancerous epithelium and stromal compartments compared to normal kidney tissue

• Prostate cancer: Primary and metastatic prostate cancer tissues exhibit elevated PSME2 expression compared to normal prostate, where expression is limited primarily to basal cells

This upregulation pattern suggests PSME2 as a potential pan-cancer biomarker with diagnostic and prognostic value .

What methodologies are recommended for evaluating PSME2's role in tumor immune microenvironment?

To comprehensively assess PSME2's role in the tumor immune microenvironment, researchers should implement a multi-modal approach:

• Correlation analysis with immune cell markers:

  • Analyze associations between PSME2 and immunomodulators (chemokines, MHC, immunostimulators, and receptors)

  • Evaluate correlations with gene markers of tumor-infiltrating immune cells

• Spatial transcriptomic analysis:

  • Examine the spatial relationships between PSME2 expression and immune cell markers (e.g., CD68 for macrophages, TLR2 for M1 macrophages)

  • Use tools like SpatialDB to map these relationships

• Single-cell sequencing:

  • Leverage single-cell platforms like TISCH to analyze PSME2 expression at cellular resolution

  • Correlate PSME2 with various functional states in cancer cells and immune populations

• Validation with immunohistochemistry:

  • Perform IHC staining for PSME2 and immune markers (e.g., PD-L1) on consecutive tumor sections

  • Conduct semi-quantitative analysis to confirm correlations observed in transcriptomic data

How does PSME2 correlate with immunotherapy response biomarkers?

PSME2 shows significant positive correlations with established immunotherapy response biomarkers:

• Immunophenoscore (IPS):

  • PSME2 expression positively correlates with IPS, suggesting association with immunogenically "hot" tumors

• Tumor Mutational Burden (TMB):

  • Higher PSME2 expression associates with elevated TMB levels, a known predictor of immunotherapy response

• T cell inflamed score:

  • Positive correlation exists between PSME2 expression and T cell inflamed score

• Immune checkpoint expression:

  • PSME2 expression correlates positively with immune checkpoint molecules including PD-L1

  • This correlation has been validated at both mRNA and protein levels

These associations suggest PSME2 could serve as a predictive biomarker for immunotherapy response, particularly in breast cancer patients .

What are the optimal antibody dilutions for different PSME2 detection methods?

Based on validated protocols, the following dilution ranges are recommended:

Each experimental system should be individually optimized as antibody performance can vary by sample type and preparation method .

How can researchers validate PSME2 antibody specificity?

A comprehensive validation approach should include:

• Positive control tissues/cells:

  • MCF-7 cells, human brain tissue, mouse pancreas tissue, and human kidney tissue have been verified as positive controls for WB applications

  • Human kidney tissue serves as a validated positive control for IHC

• Knockdown/knockout validation:

  • Transfect cell lines (e.g., CAKI-1 and 786-O) with siRNA targeting PSME2

  • Confirm knockdown efficiency via RT-qPCR and western blot before phenotypic assays

• Recombinant protein testing:

  • Use full-length human PSME2 recombinant protein for ELISA validation

  • Compare observed molecular weight (27 kDa) with calculated weight to verify target specificity

• Multiple detection methods:

  • Cross-validate results using complementary techniques (e.g., IF/ICC, WB, and flow cytometry)

  • Consistent expression patterns across methods strengthen antibody validation

What are the critical controls needed when studying PSME2 in cancer tissues?

When investigating PSME2 in cancer tissues, include these essential controls:

• Matched normal-tumor tissue pairs:

  • Always compare PSME2 expression between tumor samples and adjacent normal tissue from the same patient when possible

  • This controls for individual variation and allows for proper assessment of differential expression

• Negative controls for IHC/IF:

  • Omission of primary antibody

  • Isotype control antibody (e.g., Rabbit IgG monoclonal [EPR25A] for rabbit monoclonal anti-PSME2 antibodies)

• Cell type-specific markers:

  • Include markers for endothelial cells (CD31), immune cells, and specific tumor cells when studying the tumor microenvironment

  • This helps disambiguate PSME2 expression patterns across different cellular components

• Subcellular localization controls:

  • Include nuclear stains (e.g., DAPI) in IF studies to assess PSME2's subcellular distribution

  • This is particularly important as PSME2 localization may vary between normal and cancerous tissues

How does PSME2 affect immunoproteasome function in cancer?

PSME2 plays a multifaceted role in cancer immunoproteasome function:

• Antigen processing modification:

  • PSME2 enhances the generation of class I binding peptides by altering the proteasome's cleavage pattern

  • This affects the presentation of tumor-derived antigens on MHC class I molecules, facilitating recognition by cytotoxic T lymphocytes

• Tumor microenvironment modulation:

  • PSME2 expression correlates with increased levels of tumor-infiltrating immune cells (TIICs)

  • High PSME2 expression associates with "immuno-hot" tumor immune microenvironments characterized by enhanced T cell infiltration and activation

• Immunotherapy response:

  • PSME2 upregulation potentially enhances tumor immunogenicity through improved antigen presentation

  • This mechanism may explain why high PSME2 expression predicts better response to immunotherapy in certain cancers

• Cancer type-specific effects:

  • In breast cancer, PSME2 identifies "immuno-hot" tumors likely to respond to immunotherapy

  • In renal carcinoma, PSME2 may promote tumor invasiveness while simultaneously enhancing immunogenicity

Understanding these mechanisms is crucial for developing PSME2-targeted therapeutic strategies.

What molecular mechanisms link PSME2 to autophagy in cancer cells?

Research has revealed a complex relationship between PSME2 and autophagy in cancer cells:

• BNIP3-mediated autophagy regulation:

  • PSME2 knockdown in renal carcinoma cell lines (CAKI-1 and 786-O) enhances autophagy

  • This effect is mediated through the BCL2 interacting protein 3 (BNIP3) pathway

• Invasion and autophagy balance:

  • When PSME2 expression is knocked down in renal carcinoma cells, their invasive abilities decrease while autophagy increases

  • This suggests PSME2 may promote invasiveness by inhibiting autophagy mechanisms

• Potential therapeutic implications:

  • Targeting PSME2 could potentially inhibit tumor invasion by promoting autophagy

  • This mechanism appears distinct from PSME2's role in antigen presentation and immune recognition

Further research is needed to fully elucidate the signaling pathways connecting PSME2, autophagy, and cancer cell invasiveness across different tumor types.

How does PSME2 correlate with M1 macrophage infiltration in the tumor microenvironment?

PSME2 has emerged as a biomarker for M1 macrophage infiltration in multiple cancer types:

• Spatial distribution relationship:

  • Spatial transcriptomic analyses reveal co-localization of PSME2 expression with M1 macrophage markers (e.g., TLR2)

  • This spatial relationship is observed particularly in breast cancer and melanoma samples

• Single-cell resolution evidence:

  • Single-cell sequencing data confirm PSME2's association with macrophage functional states

  • PSME2 expression correlates strongly with M1 (pro-inflammatory) rather than M2 (immunosuppressive) macrophage signatures

• Validation through multiple approaches:

  • Correlation between PSME2 and macrophage infiltration has been established through bulk RNA-seq, single-cell RNA-seq, and spatial transcriptomics

  • Confirmatory fluorescent staining further validates this relationship at the protein level

• Pan-cancer biomarker potential:

  • The PSME2-M1 macrophage correlation persists across multiple cancer types

  • This suggests PSME2 could serve as a universal biomarker for assessing M1 macrophage infiltration in tumors

This relationship has significant implications for immunotherapy, as M1 macrophages typically promote anti-tumor immune responses.

What are the prospects for PSME2 as a therapeutic target in cancer?

PSME2 shows significant potential as a therapeutic target based on several lines of evidence:

• Differential expression pattern:

  • PSME2 is upregulated in multiple cancer types compared to normal tissues

  • This cancer-specific expression profile makes it an attractive target for selective therapy

• Dual role in cancer biology:

  • PSME2 functions both in tumor progression (invasion) and immune recognition

  • This dual role opens possibilities for combination therapies targeting both aspects

• Immunotherapy enhancement:

  • High PSME2 expression correlates with better immunotherapy response in breast cancer

  • PSME2-targeting approaches could potentially sensitize "immune-cold" tumors to immunotherapy

• Molecular docking candidates:

  • Computational screening has identified compounds that may interact with PSME2

  • These candidates could be developed into PSME2-modulating therapeutics

Research efforts should focus on developing specific PSME2 modulators and evaluating their effects on tumor growth, invasion, and immune recognition in preclinical models.

How can spatially-resolved transcriptomics enhance our understanding of PSME2 function in the tumor microenvironment?

Spatially-resolved transcriptomics offers several advantages for elucidating PSME2's role in the tumor microenvironment:

• Architectural context preservation:

  • Unlike bulk RNA sequencing, spatial transcriptomics maintains information about the physical relationships between different cell types

  • This allows researchers to observe how PSME2-expressing cells interact with immune cells and stromal components

• Heterogeneity mapping:

  • PSME2 expression is heterogeneously distributed within tumors

  • Spatial methods reveal specific patterns, such as perivascular expression or association with tumor margins

• Multi-marker co-expression analysis:

  • Simultaneous visualization of PSME2 with immune markers (CD68, TLR2) and tumor markers

  • This provides insights into the functional relationships between PSME2 and various cell populations

• Therapeutic response prediction:

  • Spatial patterns of PSME2 expression may better predict response to immunotherapy than bulk expression levels

  • Analysis of pre- and post-treatment samples could reveal spatial reorganization following therapy

Researchers should consider incorporating spatial transcriptomics alongside single-cell RNA sequencing and traditional bulk approaches for comprehensive characterization of PSME2's role in the tumor microenvironment.

What contradictions exist in current PSME2 research, and how might they be resolved?

Several apparent contradictions exist in current PSME2 research that warrant further investigation:

• Prognostic value discrepancy:

  • PSME2 correlates with better prognosis in some cancers and poorer outcomes in others

  • This discrepancy may reflect differing roles based on cancer type, stage, or predominant immune environment

  • Resolution approach: Comprehensive pan-cancer studies using consistent methodologies and stratification by molecular subtypes

• Pro-tumorigenic vs. anti-tumorigenic functions:

  • PSME2 enhances invasion in renal carcinoma but suppresses tumorigenic activity in esophageal and gastric cancers

  • This suggests context-dependent functions that may relate to the prevailing immune environment

  • Resolution approach: Mechanistic studies examining PSME2-associated pathways across multiple cancer models

• Normal vs. cancer tissue expression:

  • PSME2 is reportedly inactive in healthy individuals but active in cancer

  • Yet baseline expression is detected in normal tissues, particularly liver, pancreas, and lung

  • Resolution approach: Single-cell analyses of normal tissues to identify cell type-specific expression and activation states

• PD-L1 correlation limitations:

  • While PSME2 correlates with PD-L1 expression, PD-L1 has limitations as a biomarker due to glycosylation issues

  • This raises questions about PSME2's reliability as an immunotherapy biomarker

  • Resolution approach: Combined assessment of multiple markers alongside functional immune assays

These contradictions highlight the complex and context-dependent nature of PSME2 biology, underscoring the need for integrated multi-omics approaches in future research.

What integrated research approaches would best advance our understanding of PSME2 in cancer biology?

Advancing PSME2 research requires integrated approaches combining multiple technologies:

• Multi-omics integration:

  • Combine genomics, transcriptomics, proteomics, and metabolomics data

  • This comprehensive approach can reveal relationships between PSME2 genetic alterations, expression patterns, and functional consequences

• Spatial multi-omics:

  • Layer spatial transcriptomics with immunofluorescence and mass spectrometry imaging

  • This will map the distribution of PSME2 in relation to other molecules and cell types within the tumor microenvironment

• Functional validation through genetic manipulation:

  • CRISPR-Cas9 modification of PSME2 in relevant cell and animal models

  • Conditional knockout systems to study temporal aspects of PSME2 function

• Translational clinical studies:

  • Prospective evaluation of PSME2 as a biomarker in immunotherapy trials

  • Collection of longitudinal samples to assess changes in PSME2 expression during treatment

Such integrated approaches will provide a more complete picture of PSME2's role in cancer development, progression, and treatment response.